Novo Nordisk has begun phase III trial with antibody

In the beginning of September, Novo Nordisk started a phase III with the antibody ziltivekimab, which the company received in a million-dollar acquisition of the US-based company Corvidia Therapeutics last year, according to database Clinicaltrials.gov, which collects information about clinical studies, and Novo Nordisk confirms as much in comment to MedWatch.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk creates new RNA and gene therapy unit
For subscribers